Coagulation Studies in Liver Disease

Acke Hallén; Inga Marie Nilsson

doi:10.1055/s-0038-1654805

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1964; 11(01): 051-063
DOI: 10.1055/s-0038-1654805

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

Coagulation Studies in Liver Disease^[*]

Acke Hallén

¹Coagulation Laboratory (Head: Associate Professor Inga Marie Nilsson) and the Medical Clinic (Head: Professor Jan Waldenstrom) University of Lund, Allmänna Sjukhuset, Malmö, Sweden

,

Inga Marie Nilsson

¹Coagulation Laboratory (Head: Associate Professor Inga Marie Nilsson) and the Medical Clinic (Head: Professor Jan Waldenstrom) University of Lund, Allmänna Sjukhuset, Malmö, Sweden

› Author Affiliations

Abstract

Summary

Various caogulation factors were studied in 20 cases of liver cirrhosis for their possible diagnostic value. Special attention was given to determination of antithrombin (AT), and AT values were also studied in a series of hepatitis and obstructive jaundice.

The P & P test was decreased in 75%, the factor V content in 83%, the factor IX content in 40% and the platelet count in 55% of the cases of liver cirrhosis.

Increased fibrinolytic activity was noted in 5 cases. Only 2 cases had significantly decreased fibrinogen levels and most probably due to fibrinolysis. The AHF (f. VIII) level was slightly decreased in 2 cases, one of which had fibrinolysis, while the other had normal AHF levels.

In 12 of 18 cases of liver cirrhosis the AT II and III was decreased and only in one case was it increased but the decreased values deviated only slightly from the normal range. AT II and III in 23 cases of obstructive icterus and in 19 cases of hepatitis gave practically normal values.

Judging from our results determination of P & P and factor V is valuable in the diagnosis of liver cirrhosis. Determination of AT II and III by use of an improved method proved not to give any further help in the diagnosis of liver cirrhosis or the differential diagnosis between cirrhosis, hepatitis and obstructive jaundice.

Full Text

References

References
1 Alagille D, Hartmann L, Fauvert R. Etude analytique du temps de Quick au cours de l’insuffisance hépatique par les dosages différentiels de la prothrombin, de la proconvertine et de la proaccélérine. Sem. Hôp. Paris. 29: 3375 1953;
2 Alagille D, Soulier J. P. Action des enzymes protéolytiques sur le sang total in vitro ; modifications des facteurs de coagulation et du complément. Sem. Hôp. Paris. 32: 355 1956;
3 Alexander B, Goldstein R. Coagulation defect in hepatic disorders: deficiency of prothrom- bin-conversion accessory substances. J. clin. Invest. 29: 795 1950;
4 Andersson L, Nilsson I. M, Olow B. Fibrinolytic activity in man during surgery. Thrombos. Diathes. haemorrh. (Stuttg.) 07: 391 1962;
5 Beaumont J. L, Beaumont V, Domart A. Réchèrches sur l’activité fibrinolytique spontanée dn plasma dans les cirrhoses dn foie. Rev. franç. Etudes clin. biol. 01: 667 1956;
6 Björkman S. E. A new method for enumeration of the platelets. Acta haemat. 22: 377 1959;
7 Blombäck B, Blombäck M. Purification of bovine and human fibrinogen. Arkiv for kemi. 10: 415 1956;
8 Bradlow B. A, Antonis A, Bersohn I. Fibrinolytic activity in South African Bantu and white male subjects. S. Afr. med. J. Sci. 27: 15 1962;
9 Broicher H, Egli H, Kesseler K, Oberhoffer G. Über die Bedeutung gerinnungsphysiologischer Untersuchungen bei akuten und chronischen Lebererkrankungen. Dtsch. Arch. klin. Med. 205: 292 1958;
10 Broicher H, Egli H, Kesseler K. Clotting tests and liver function. Germ. med. Mth. 05: 161 1960;
11 Cowling D. C. Coagulation defects in liver disease. J. clin. Path. 09: 347 1956;
12 Dausset J, Paraf A, Bergerot-Blondel Y, Garoli J. La fibrinolyse latente des cirrhoses du foie. Ann. Rech. méd. 32: 1033 1956;
13 Egeberg O. Antihemophilic A factor (tactor VIII) and fibrinogen in human blood. Scand. J. clin. Lab. Invest. 14: 230 1962;
14 Fearnley R. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet. I: 450 1956;
15 Fell G, Ivanovic N, Johnsson A. S, Seegers W. H. Differentiation of plasma antithrombin activities. Proc. Soc. exp. Biol. 85: 199 1954;
16 Finkbiner K. B, McGovern J. J, Goldstein R, Bunker J. P. Coagulation defects in liver disease and response to transfusion during surgery. Amer. J. Med. 26: 199 1959;
17 Griffith W. H. Plasma antithrombin in thrombosis, haemorrhage and liver disease. L. Jab. clin. Med. 40: 367 1952;
18 Hallen A. A method for measuring antithrombin. Thrombos. Diathes. haemorrh. (Stuttg.) 08: 56 1962;
19 Harrington W. J, Desforges F. J, Minkel H. P, Crow C. B, Stohlman F. The bleeding tendency in hepatocellular and obstructive jaundice. Bull. New Engl. med. Cent. 12: 121 1950;
20 Hedenberg L, Korsan-Bengtsen K. Clotting tests and other tests of the hemostatic mechanism in cirrhosis of the liver and their diagnostic significance. Acta med. scand. 172: 229 1962;
21 Imdahl H, Egli H, Kesseler K, Hennrick G. Über den Wert gerinnungsphys. Untersuchungen bei Erkrankungen der Leber und des Gallengangsystems in der Chirurgie. Arztl. Wschr. 12: 481 1957;
22 Innerfield I, Angrist A, Boyd L. J. Plasma antithrombin titer in incipient and advanced liver failure. Gastroenterology. 20: 417 1952;
23 Jürgens J. Neue Bestimmungsmethoden und Bedeutung der Antithrombine für die Klinik. Klin. Wschr. 35: 303 1957;
24 Jürgens R, Trautwein H. Über Fibrinopenie (Fibrinogenopenie) beim Erwachsenen nebst Bemerkungen über die Herkunft des Fibrinogens. Dtsch. Arch. klin. Med. 169: 28 1930;
25 Koller F, Fritschy W. Über die Bedeutung des Antithrombins. Acta med. Helv. 14: 263 1947;
26 Kwaan H. C, McFadzean AJS, Cook J. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet. I: 133 1956;
27 Loeliger A, Hers JFPh. Chronic antithrombinaemia (antithrombin V) with haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia. Thrombos. Diathes. haemorrh. (Stuttg.) 01: 499 1957;
28 Miller L. L, Bale W. F. Synthesis of all plasma protein fractions except gamma globulins by the liver. J. Exper. Med. 99: 125 1954;
29 Neumayr A, Parzer O. Die klinische Bedeutung der Antithrombinteste. Dtsch. med. Wschr. 81: 161 1956;
30 de Nicola P, Soardi F. Fibrinolysis in liver diseases. Study of 109 cases by means of the fibrin plate method. Thrombos. Diathes. haemorrh. (Stuttg.) 02: 290 1958;
31 Niewiarowski S, Kowalski E. Formation of an antithrombinlike anticoagulant during proteolysis of fibrinogen. Bull. Acad. pol. Sci. 05: 169 1957;
32 Niléhn J-E. On symptomatic antihaemophilic globulin (AHF) deficiency. Acta med. scand. 171: 491 1962;
33 Nilsson I. M, Björkman S. E, Andersson L. Clinical experiences with e-aminocaprioc acid (e-ACA) as an antifibrinolytic agent. Acta med. scand. 170: 487 1961;
34 Nilsson I. M, Blombäck M, Francken I. v. On an inherited autosomal hemorrhagic diathesis with antihaemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta med. scand. 159: 35 1957;
35 Nilsson I. M, Blombäck M, Ramgren O. Haemophilia in Sweden. I. Coagulation studies. Acta med. scand. 170: 665 1961;
36 Nilsson I. M, Nosslin B, Serin F. Personal communications..
37 Nilsson I. M, Olow B. Determination of fibrinogen and fibrinogenolytic activity. Thrombos. Diathes. haemorrh. (Stuttg.) 08: 297 1962;
38 Nilsson I. M, Olow B. Fibrinolysis induced by streptokinase in man. Acta chir. scand. 123: 247 1962;
39 Nilsson I. M, Sjoerdsma A, Waldenstrom J. Antifibrinolytic activity and metabolism of s-aminocaproic acid in man. Lancet. I: 1322 1960;
40 Owren P. A. The diagnostic and prognostic significance of plasma prothrombin and factor V levels in parenchymatous hepatitis and obstructive jaundice. Scand. J. clin. Lab. Invest. 01: 131 1949;
41 Rapaport S. I, Ames S. B, Mikkelsen S, Goodman J. R. Plasma clotting factors in chronic hepatocellular disease. New Engl. J. Med. 263: 278 1960;
42 Ratnoff O. D. Studies on proteolytic enzyme in human plasma. IV. The rate of lysis of plasma clots in normal and diseased individuals, with particular reference to hepatic disease Bull. Johns Hopkins Hosp. 84: 29 1949;
43 Risak E. Die Fibrinopenie. Z. klin. Med. 128: 605 1935;
44 Sokal G, Schmidt F, Hörder M. H. Die Antithrombinaktivitäten des Plasmas bei Lebererkrankungen und Verschlußikterus. Klin. Wschr. 33: 934 1955;
45 Stefanini M. The hemorrhagic diathesis of liver dysfunction and obstruction jaundice. Proc. 3 internat, congress soc. of haemat. Cambridge; 1950: 484.
46 Weaver W. T, Anlyan W. G, Postlethweit R. W. Blood coagulation factors in liver disease. Surgery. 50: 207 1961;
47 Witte S, Dirnberger P. Klinische Untersuchungen über die Gerinnungsfaktoren Prothrombin, Faktor V und Faktor VII bei Lebererkrankungen und ihre Beeinflussung durch Vitamin K, und Synka-Vit. Klin. Wschr. 31: 781 1953;
48 Witte S, Dirnberger P. Plasma-antithrombin und Thrombininhibitor bei Leberparenchym - und Gallenwegskrankheiten. Klin. Wschr. 33: 705 1955;
49 Volkert M. Studies on the antithrombin content of the blood and it’s relation to heparin. Acta physiol, scand. suppl. 15 1942
50 Zetterqvist E, Francken I. v. Koagulationsfaktorerna vid leversjukdom. Nord. Med. 69: 81 1963;

Coagulation Studies in Liver Disease[*]

Coagulation Studies in Liver Disease^[*]